UNIRETIC Drug Patent Profile
✉ Email this page to a colleague
When do Uniretic patents expire, and when can generic versions of Uniretic launch?
Uniretic is a drug marketed by Ucb Inc and is included in one NDA.
The generic ingredient in UNIRETIC is hydrochlorothiazide; moexipril hydrochloride. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; moexipril hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for UNIRETIC?
- What are the global sales for UNIRETIC?
- What is Average Wholesale Price for UNIRETIC?
Summary for UNIRETIC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 47 |
| Clinical Trials: | 3 |
| Patent Applications: | 4,806 |
| Drug Prices: | Drug price information for UNIRETIC |
| DailyMed Link: | UNIRETIC at DailyMed |
Recent Clinical Trials for UNIRETIC
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Teva Pharmaceuticals USA | Phase 1 |
| Paddock Laboratories, Inc. | Phase 1 |
Paragraph IV (Patent) Challenges for UNIRETIC
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| UNIRETIC | Tablets | hydrochlorothiazide; moexipril hydrochloride | 7.5mg/12.5mg, 15 mg/25 mg and 15 mg/12.5 mg | 020729 | 1 | 2004-01-15 |
US Patents and Regulatory Information for UNIRETIC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ucb Inc | UNIRETIC | hydrochlorothiazide; moexipril hydrochloride | TABLET;ORAL | 020729-001 | Jun 27, 1997 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Ucb Inc | UNIRETIC | hydrochlorothiazide; moexipril hydrochloride | TABLET;ORAL | 020729-003 | Feb 14, 2002 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Ucb Inc | UNIRETIC | hydrochlorothiazide; moexipril hydrochloride | TABLET;ORAL | 020729-002 | Jun 27, 1997 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for UNIRETIC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ucb Inc | UNIRETIC | hydrochlorothiazide; moexipril hydrochloride | TABLET;ORAL | 020729-001 | Jun 27, 1997 | ⤷ Subscribe | ⤷ Subscribe |
| Ucb Inc | UNIRETIC | hydrochlorothiazide; moexipril hydrochloride | TABLET;ORAL | 020729-002 | Jun 27, 1997 | ⤷ Subscribe | ⤷ Subscribe |
| Ucb Inc | UNIRETIC | hydrochlorothiazide; moexipril hydrochloride | TABLET;ORAL | 020729-002 | Jun 27, 1997 | ⤷ Subscribe | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for UNIRETIC
See the table below for patents covering UNIRETIC around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 1331614 | DERIVES ACYL SUBSTITUES D'ACIDES 1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIQUES (SUBSTITUTED ACYL DERIVATIVES OF 1,2,3,4-TETRAHYDROISOQUINOLINE- 3-CARBOXYLIC ACIDS) | ⤷ Subscribe |
| Canada | 1331615 | DERIVES ACYL SUBSTITUES D'ACIDES 1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIQUES (SUBSTITUTED ACYL DERIVATIVES OF 1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACIDS) | ⤷ Subscribe |
| Australia | 7541681 | ⤷ Subscribe | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for UNIRETIC
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0454511 | 99C0009 | Belgium | ⤷ Subscribe | PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015 |
| 0480717 | 98C0025 | Belgium | ⤷ Subscribe | PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215 |
| 0454511 | SPC/GB99/008 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
